Leading the Way in Life Science Technologies

GEN Exclusives

More »

Best of the Web

More »
Feb 01, 2011 (Vol. 31, No. 3)

AIDSmap

URL:www.aidsmap.com
  • Well-organized, clear language
  • None

For patients, their friends and family, and members of the general community, it can sometimes be a daunting task to maneuver one’s way through the sea of information that’s available about HIV and AIDS. Aidsmap.com simplifies this process of getting the information you want by providing an easy-to-navigate website full of easy-to-understand facts. (In fact, the only unclear information I found on the site was what NAM—the nonprofit organization behind the site—stands for. A minor point, but frustrating nonetheless…) The website succeeds in providing information for a general audience not only about the “basics of HIV”, but also on a number of topics such as transmission and prevention, social and legal issues, and how HIV works. Additionally, the E-atlas is a wonderful resource to search for HIV/AIDS organizations and services around the world.

  • Key:
  • Strong Points
  • Weak Points
  • Ratings:
  • Excellent
  • Very Good
  • Good


*The opinions expressed are solely those of the author(s) and should not be construed as reflecting the viewpoints of the publisher, Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., the publishing house, or employees and affiliates thereof.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »